Tick-Borne Diseases in Dogs: Comprehensive Pathogen List, Curability, and Clinical Management

Introduction

Tick-borne diseases (TBDs) represent a major category of vector-borne infections in companion animals globally. These pathogens include bacteria, protozoa, and rickettsial organisms transmitted primarily by ixodid ticks. The geographic distribution of TBDs is expanding due to climate change, habitat alteration, and increased animal movement [1]. In Latin America, a wide range of vector-borne pathogens have been documented in dogs, including Anaplasma, Babesia, Borrelia, Ehrlichia, Rickettsia, Bartonella, Mycoplasma, and Hepatozoon species [1]. In the Prairie Provinces of Canada, important canine zoonotic tick-borne pathogens include Anaplasma phagocytophilum, Borrelia burgdorferi, and others [2]. The clinical consequences range from subclinical infection to fatal disease. Understanding the full pathogen spectrum, curability, and evidence-based clinical management is essential for veterinary practitioners.

This article provides a comprehensive reference on tick-borne diseases in dogs, organized by pathogen type, with detailed discussion of curability, diagnostic approaches, and therapeutic protocols. A clinical decision flowchart is included to guide diagnostic workflows.

Comprehensive Pathogen List

The following table summarizes the major tick-borne pathogens affecting dogs, their primary vector ticks, disease names, and general curability status. Curability is defined as the ability to achieve microbiological elimination or sustained clinical remission with available therapies.

Bacterial Pathogens

Ehrlichia canis

Ehrlichia canis is the causative agent of canine monocytic ehrlichiosis (CME). The organism is transmitted by the brown dog tick (Rhipicephalus sanguineus) and has a worldwide distribution [1]. In Latin America, E. canis is among the most frequently reported tick-borne pathogens in dogs [1]. The bacterium infects monocytes and macrophages, leading to a complex pathobiology involving immune-mediated destruction of platelets and bone marrow suppression.

Clinical phases include acute, subclinical, and chronic. The acute phase presents with fever, lethargy, lymphadenomegaly, and thrombocytopenia. The chronic phase may manifest as pancytopenia, epistaxis, and secondary infections. Diagnosis is confirmed by blood smear cytology for morulae (though sensitivity is low) or by molecular assays targeting the 16S rRNA or dsb genes. Serologic testing via commercial ELISA kits detects anti-E. canis antibodies but cannot distinguish active from past infection.

Treatment of CME with doxycycline (10 mg/kg/day or 5 mg/kg BID for 28 days) is considered standard. In chronic cases, repeated or longer courses may be needed. Supportive care includes transfusion for severe anemia or bleeding. Prognosis is favorable if treatment is initiated in the acute phase, whereas chronic severe CME carries a guarded prognosis. Standard veterinary formularies recommend doxycycline as first-line therapy.

Anaplasma phagocytophilum and Anaplasma platys

Anaplasma phagocytophilum causes granulocytic anaplasmosis, transmitted primarily by Ixodes scapularis and I. pacificus in North America [2]. The pathogen infects neutrophils, leading to fever, lethargy, lameness, and thrombocytopenia. Diagnosis is made by PCR or serology. Anaplasma platys infects platelets, causing cyclical thrombocytopenia, with clinical signs often milder.

Both species respond well to doxycycline (10 mg/kg/day for 14 21 days). Relapses are uncommon. Tick prevention is the mainstay of prophylaxis. In Canada, A. phagocytophilum is a recognized pathogen in dogs, particularly in regions with Ixodes tick populations [2].

Borrelia burgdorferi

Lyme borreliosis in dogs results from infection with Borrelia burgdorferi sensu stricto, transmitted by Ixodes ticks. The disease is endemic in the northeastern and upper midwestern United States and parts of Canada [2]. Clinical signs include fever, acute onset lameness, lymphadenopathy, and rarely glomerulonephritis. Many infected dogs remain asymptomatic.

Diagnosis relies on serology (C6 peptide ELISA combined with quantitative antibody tests) and Western blot confirmation. PCR on blood or synovial fluid is less sensitive due to spirochetemia being transient.

Treatment with doxycycline (10 mg/kg/day for 30 days) is effective for clinical resolution. However, the spirochete may persist in tissues; therefore, complete microbiologic cure is not reliably achieved. Doxycycline therapy reduces clinical signs and prevents disease progression. Vaccination is available but does not prevent infection; it reduces the risk of clinical disease. Tick control remains critical.

Rickettsia rickettsii and Other Rickettsiae

Rickettsia rickettsii causes Rocky Mountain spotted fever (RMSF), a severe, potentially fatal disease in dogs. Transmission occurs via Dermacentor and Rhipicephalus ticks. The pathogen induces vasculitis, leading to fever, edema, petechiation, and neurologic signs. Diagnosis is by serology (paired titers) or PCR; immunohistochemistry on biopsy is confirmatory.

Treatment with doxycycline (10 mg/kg/day for 7 14 days) is highly effective if initiated early. Delayed treatment increases mortality. Other Rickettsia species (R. parkeri, R. amblyommatis) produce milder clinical disease and have been reported in Latin America [1].

Protozoan Pathogens

Babesia canis and Babesia gibsoni

Babesia canis is a large piroplasm transmitted by Dermacentor ticks, while Babesia gibsoni is a small piroplasm often associated with Rhipicephalus and Haemaphysalis ticks. Both cause hemolytic anemia, fever, hemoglobinuria, and splenomegaly. Babesia infections are widespread in Latin America [1] and are a concern in Canada as well [2].

Diagnosis is by blood smear examination (intraerythrocytic merozoites) or PCR. Treatment involves antiprotozoal drugs: imidocarb dipropionate (6.6 mg/kg IM once, repeated in 2 weeks) for B. canis; atovaquone combined with azithromycin for B. gibsoni. These treatments reduce parasitemia but often fail to eliminate the organism completely, resulting in a carrier state. Blood transfusion may be necessary in severe anemia.

Hepatozoon canis and Hepatozoon americanum

Hepatozoonosis is unique among TBDs because transmission occurs via ingestion of an infected tick, not by bite. Hepatozoon canis occurs globally, while H. americanum is found in the southeastern United States. Clinical signs include fever, myositis, periosteal bone proliferation (in H. americanum), and cachexia.

Diagnosis is by muscle biopsy or PCR. Treatment is challenging: toltrazuril, sulfadiazine-pyrimethamine, and clindamycin combinations may reduce clinical signs, but parasite elimination is rarely achieved. Relapses are common. Prevention relies on rigorous tick control and preventing dogs from ingesting ticks.

Clinical Management

A systematic approach to managing suspected TBDs involves history, physical examination, clinicopathologic testing, and targeted diagnostics. The following decision flowchart illustrates a typical clinical workflow.

flowchart TD
    A[Dog presents with fever, lethargy, lameness, or bleeding] --> B{History of tick exposure?}
    B -->|Yes| C[Perform CBC, biochemistry, blood smear]
    B -->|No| D["Consider other causes; re-evaluate exposure"]
    C --> E{Thrombocytopenia or anemia?}
    E -->|Yes| F["Serology: Ehrlichia, Anaplasma, Borrelia, Babesia<br>+ PCR panel for vector-borne pathogens"]
    E -->|No| G[Serology for Lyme and others if geographic risk]
    F --> H[Positive for specific pathogen]
    H --> I["Initiate targeted therapy:<br>- Doxycycline for Ehrlichia/Anaplasma/Rickettsia<br>- Antiprotozoals for Babesia/Hepatozoon<br>- Long-term doxy for Lyme"]
    G --> J[If clinical suspicion remains, consider PCR<br>and convalescent serology]
    I --> K["Supportive care: fluids, transfusion if needed,<br>NSAIDs cautiously with platelet count monitoring"]
    K --> L["Re-check CBC; monitor clinical response"]
    L --> M{Response in 48-72 hours?}
    M -->|Yes| N["Complete course; implement tick prevention"]
    M -->|No| O["Re-evaluate diagnosis; consider co-infections,<br>drug resistance, alternative pathogens"]

Diagnostic Modalities

First-line diagnostics include complete blood count (CBC), blood smear evaluation, and biochemistry. Thrombocytopenia is a hallmark of many TBDs, particularly ehrlichiosis and anaplasmosis. Blood smears can reveal morulae (Ehrlichia, Anaplasma) or intraerythrocytic parasites (Babesia). Serology using commercial ELISA kits detects antibodies to E. canis, A. phagocytophilum, B. burgdorferi, and R. rickettsii. Molecular diagnosis by PCR provides high sensitivity and specificity for active infections and can detect organisms before seroconversion.

Co-infections are common; one animal may harbor multiple tick-borne pathogens simultaneously [1]. Therefore, panel-based testing is recommended in endemic regions.

Therapeutic Principles

Doxycycline is the cornerstone therapy for most bacterial tick-borne diseases, including ehrlichiosis, anaplasmosis, rickettsiosis, and Lyme borreliosis. The standard dose is 10 mg/kg per day (or 5 mg/kg BID) administered orally for 14 to 28 days depending on the pathogen and clinical response. For Babesia and Hepatozoon, antiprotozoal agents are required. Imidocarb dipropionate is approved for use in dogs in many countries. For Babesia gibsoni, atovaquone plus azithromycin has shown superior efficacy.

Supportive care includes intravenous fluids, blood transfusions, antiemetics, and nutritional support. Nonsteroidal anti-inflammatory drugs (NSAIDs) should be used cautiously in animals with thrombocytopenia because of bleeding risk. Glucocorticoids may be indicated in immune-mediated complications of ehrlichiosis or anaplasmosis but can exacerbate Tick-borne disease.

Prevention

Prevention is far more effective than treatment. Topical and oral acaricides reduce tick attachment and feeding. The geographic distribution of ticks and their pathogens necessitates region-specific prophylaxis planning. In Latin America, the predominant tick species is Rhipicephalus sanguineus, which transmits E. canis, A. platys, B. vinsonii, and others [1]. In Canada, Ixodes species are the primary vectors for B. burgdorferi and A. phagocytophilum [2]. Regular tick checks, environmental management, and owner education are integral to integrated tick-borne disease prevention.

Conclusion

Tick-borne diseases in dogs encompass a diverse array of pathogens with varying curability and clinical management strategies. Bacterial infections (Ehrlichia, Anaplasma, Rickettsia, Borrelia) are generally treatable with doxycycline, although complete microbiologic elimination may not always be achieved. Protozoan infections (Babesia, Hepatozoon) require specific antiprotozoal drugs and often result in persistent carrier states. Comprehensive diagnostic testing, prompt and appropriate therapy, and rigorous tick prevention are essential to reduce morbidity and mortality. Continued surveillance and reporting of TBDs in regions such as Latin America and Canada remain vital for understanding epidemiologic trends and informing clinical practice [1, 2].

References

[1] Maggi, R., Krämer, F. A review on the occurrence of companion vector-borne diseases in pet animals in Latin America. Parasites & Vectors, 2019. Available at: https://www.semanticscholar.org/paper/71c7cb44d560f3555c27b2cfbc047841028449f0

[2] Sims, E., Epp, T. Defining important canine zoonotic pathogens within the Prairie Provinces of Canada. The Canadian Veterinary Journal, 2021. Available at: https://www.semanticscholar.org/paper/a7e8f56b672a3a1fe69fbe3856f8bcc4ac1d845f General references: Merck Veterinary Manual (standard textbook) for treatment guidelines where cited in text. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.